Design and synthesis of EGFR dimerization inhibitors and evaluation of their potential in the treatment of psoriasis

Autor: Rosaleen J. Anderson, Donna Petch, Paul W. Groundwater, Simon P. Mackay, Ran Liu, Suja E. George, Andrew Paul, David A. P. Small, David E. Hibbs, Anne E. Cunningham
Rok vydání: 2012
Předmět:
Zdroj: Bioorganic & Medicinal Chemistry. 20:5901-5914
ISSN: 0968-0896
DOI: 10.1016/j.bmc.2012.07.048
Popis: Hit compounds from in silico screening for inhibitors of the EGFR dimerization process were evaluated for their anti-proliferative (CCD-1106 keratinocytes) and anti-oxidant (TBA assay) activity and their effect on EGFR dimerization (BS(3) chemical crosslinking assay). 7-Benzyl-8-{N'-[1-(3-ethoxy-4-hydroxyphenyl)meth-(Z)-ylidene]hydrazino}-1,3-dimethylxanthine 2a (127 μM) leads to 37% inhibition of p-EGFR dimerization in the CCD-1106 cell line and also inhibits phosphorylation of proteins in the MAPK/ERK pathway, ERK 1/2 and p-38. Based on this initial data, 2a was selected for further study and was evaluated for its anti-proliferative activity in a range of keratinocyte (CCD-1106, HaCaT and NHEK) and monocyte (ThP1 and U937) cell lines. Xanthine 2a is pro-apoptotic in HaCaT keratinocytes, as shown by electron microscopy, caspase 3/7, and annexin V-FITC/PI flow cytometric assays. It is significantly less cytotoxic than the established antipsoriatic agent dithranol 14, as determined by MTT and LDH release assays, and thus has potential as a lead compound for the treatment of psoriasis.
Databáze: OpenAIRE